HCP Live June 5, 2024
Tim Smith

The VIO Skin Platform by Enspectra Health was designed to assess lesions indicating either basal cell carcinoma or squamous cell carcinoma.

An announcement by Enspectra Health, a company known for its focus on health technology, indicated that the US Food and Drug Administration (FDA) awarded a Breakthrough Device Designation to Enspectra’s advanced artificial intelligence (AI)-powered ‘VIO Skin Platform’ (VIO).1

The company’s AI platform was designed with the purpose of assessing lesions that could indicate the presence of squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) among individuals deemed to be high-risk. These prevalent forms of skin cancer remain an issue for many such patients and early identification can be crucial, especially given the reported delays in screening appointments that...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Medical Devices, Technology
Related Articles:
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
Trump's Picks for Top Health Jobs Not Just Team of Rivals but 'Team of Opponents'
FDA updates definition of 'healthy'
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.

Share This Article